Scream Cream: the monograph

Scream cream is the rare product whose central question, does it work, is unanswerable as asked, because there is no it: every compounding pharmacy builds its own recipe under the same nickname. This site verified the formulas at two pharmacies and found three different products, from a six-drug blend (sildenafil, aminophylline, L-arginine, pentoxifylline, ergoloid, phentolamine) to a three-drug cream (theophylline 3%, arginine 6%, sildenafil 2%) to a sildenafil-free variant, with one order page inviting custom strengths. No blend as sold has ever been through a published randomized trial: a documented search, not a guess.

So this page does what a trial never has: it takes the blend apart. The ingredients have separable records, and they are printed here at their true size: topical sildenafil missed its primary endpoints in a 200-woman trial (one subset improved), oral sildenafil is null in broad populations and positive in narrow ones, the methylxanthines that anchor most recipes have zero arousal studies, and the one drug with a real arousal-cream trial record, alprostadil, is not in any formula we verified. No drug at all is approved for female sexual arousal disorder; the two approved sexual-medicine drugs treat low desire, a different diagnosis, and their modest numbers are printed in the comparison table.

The concept is borrowed male sexual medicine: take vasodilators, put them in a cream, apply it to the clitoris and vulva, and let increased blood flow do for arousal what it does for erection. The nickname sells the promise. The ingredients tell the sourcing story: sildenafil from erectile dysfunction tablets, aminophylline and theophylline from asthma therapy (aminophylline's only topical human record is 1990s thigh-fat creams, a fad one pharmacotherapy review closed by calling an unproven 'dream cream'), pentoxifylline from claudication, ergoloid mesylates from a 1950s dementia drug, phentolamine from blood-pressure emergencies, and L-arginine from the supplement aisle. Arousal complaints are common, affecting up to a quarter of American women by self-report, which is why a product this untested still finds a market.

Three regulatory facts frame everything else. First, no FDA-approved product named scream cream exists: the Drugs@FDA query returns no matches, and FDA states that compounded drugs are not FDA-approved and their safety, effectiveness and quality are not verified before marketing. Second, no drug is approved for female sexual arousal disorder at all, from any manufacturer, in any form. Third, not one of the seven ingredients across documented formulas has an approved topical form: sildenafil is approved oral and intravenous only, alprostadil injectable and urethral, aminophylline oral, injectable and rectal, theophylline oral and injectable, phentolamine injectable and ophthalmic, pentoxifylline oral, ergoloid sublingual and oral, and arginine as an IV diagnostic. Every documented recipe is therefore a stack of route improvisations.

The legal pathway is section 503A: a prescriber writes for an individual patient, a licensed pharmacy compounds the cream, and the transaction is lawful without any FDA review of the formula. That asymmetry, legal to sell but never evaluated, is the honest core of the scream cream story, and it is why this site grades ingredients instead of repeating marketing.

This section is the pack's spine, because formula variability is not a footnote here, it is the product's defining property. Verified 2026-08-14 with pages archived: CareFirst Specialty Pharmacy advertises six actives (sildenafil, aminophylline, L-arginine, pentoxifylline, ergoloid mesylate, phentolamine mesylate). Kare Rx sells a three-drug cream (theophylline 3%, arginine 6%, sildenafil 2%) in a 30-gram metered pump, plus a sildenafil-free variant named Climax Cream (theophylline 3%, arginine 6%, ergoloid mesylate 0.05%, pentoxifylline 5%), and invites custom strengths on its order page. Three recipes, two pharmacies, one nickname.

The consequence is worth stating mechanically: any claim about scream cream that does not name a formula is a claim about nothing in particular. Efficacy, side effects and interaction risk are properties of specific drugs at specific strengths; a cream that swaps sildenafil for theophylline, or drops sildenafil entirely, changes all three. The pharmacy pages documenting these formulas are marketing, cited here only as evidence of what is sold, never as evidence that any of it works; no formula has trial data, and FDA reviews none of them.

The pitch is one sentence: vasodilators increase genital blood flow, so a vasodilator cream should increase arousal. The first half is real pharmacology: sildenafil inhibits PDE5, methylxanthines inhibit phosphodiesterases nonselectively, phentolamine blocks alpha receptors, and oral sildenafil measurably increased vaginal vasocongestion in laboratory studies. The second half is where the evidence pushes back, twice. In the same laboratory studies, the extra engorgement did not produce extra subjective arousal: women reported more arousal for whichever pill they believed was sildenafil, and half guessed wrong. And MRI work in women with arousal disorder found most had normal clitoral engorgement to begin with, and sildenafil added nothing beyond placebo, leading the authors to conclude the disorder is not predominantly a blood-flow problem.

A rat study of alprostadil cream adds the one mechanistic wrinkle worth knowing: intravaginal application excited hypothalamic neurons and increased central oxytocin expression, suggesting genital-to-brain signaling rather than plumbing alone. It is a rat finding about a drug scream cream does not contain, and it is labeled as such in the study table.

Start where an honest page must: no scream cream blend as sold has any published randomized trial, or any published study of any design. The PubMed search for the product name returns four records about ice cream acoustics, dental cold sensitivity and food chemistry. Everything below is therefore ingredient evidence or neighboring-product evidence, graded row by row in the study table with species and compound labeled on every row, because the difference between 'a trial of this cream' and 'a trial of one ingredient, by another route, in another population' is the difference this market blurs.

The closest real test is investigational sildenafil cream 3.6% (a fixed formula, not the compounded product): 200 women with arousal disorder, 12 weeks, no significant difference from placebo cream on the co-primary endpoints, with an exploratory post hoc subset (arousal disorder without orgasmic dysfunction) improving at P=.04, in an industry-run program whose earlier 31-woman crossover was never published. Oral sildenafil splits by population: null in the 781-woman broad trial, after spinal cord injury, and on MRI engorgement; positive in women aged 22 to 28, in antidepressant-associated dysfunction, and on genital endpoints in desire-intact postmenopausal women. The pattern reads consistently: the narrower and more arousal-specific the population, the better sildenafil looks; mixed populations dilute it to null.

The rest of the recipe thins out fast. Aminophylline and theophylline: zero female-arousal studies; their topical record is thigh-fat trials (one positive series with undetectable blood levels, one null independent RCT). Topical L-arginine alone: zero studies. Pentoxifylline: zero. Ergoloid: one male ED trial of a three-drug cream. Phentolamine: a six-woman pilot and a 41-woman study whose signal appeared only in estrogen-replete women. And the drug that actually owns the FSAD-cream literature, alprostadil, with four RCTs including a 400-woman positive study, appears in none of the formulas this site verified. The evidence explorer tool renders every one of these rows with its citation.

Numbers, with their scales. Topical sildenafil cream 3.6%, ITT population: no significant co-primary difference; post hoc subset: arousal-sensation domain +2.03 versus +0.08, P=.04, a subset finding awaiting confirmation. Topical alprostadil at its best (900 mcg, Chinese RCT): arousal success 53.9% versus 33.1% on placebo, about 21 percentage points. Oral sildenafil where it worked: JAMA antidepressant trial, 0.8 points on a global sexual-function scale (95% CI 0.6 to 1.0). For calibration, the approved desire drugs: bremelanotide moved desire +0.30 to +0.42 on a 1.2-to-6.0 scale with satisfying sexual events unchanged; flibanserin added about half a satisfying event per month with evidence graded very low. Real effects in this field are small and hard-won; a compounded blend with zero trials should not be assumed to beat any of them.

If the underlying issue is low desire rather than arousal, two FDA-approved drugs exist, and the honest comparison is between their modest printed numbers and their specific risks: bremelanotide (Vyleesi), an as-needed autoinjector, desire +0.30 to +0.42 placebo-adjusted, satisfying sexual events unchanged, nausea in 40%; and flibanserin (Addyi), a nightly tablet, about half an additional satisfying event per month, boxed warning for hypotension and syncope with alcohol, CYP3A4 inhibitors or liver impairment. Neither treats arousal disorder, for which nothing is approved. One over-the-counter product class has blend-level RCTs: the botanical oil Zestra, positive in a 20-woman crossover and a 256-woman parallel trial, with genital burning in 14.6% and no shared ingredient with scream cream. Full rows and citations are in the comparison tables.

There is no validated dose, because there is no validated product: dosing instructions are set by each pharmacy for its own formula, typically a metered-pump or pea-sized amount applied before sexual activity. The strengths themselves vary between recipes (sildenafil 2% here, theophylline 3% there, six drugs at unstated strengths elsewhere), so 'one dose' delivers different drugs at different amounts depending on the pharmacy. For calibration, the neighboring trials used fixed, premeasured doses: alprostadil at 500 to 1500 mcg per application, and investigational sildenafil cream at a defined 3.6% formulation. This section is education about what is documented, not an instruction; the dispensed product's label governs.

Documented practice across sources: applied to the clitoris and external genitalia before sexual activity, with pharmacy instructions varying by formula. The trials of neighboring creams applied product to the vulva or clitoris immediately before intercourse or 30 minutes before stimulation. Three practical notes from the trial literature rather than from marketing: local burning or application-site discomfort, when it occurs, is the class's signature early effect; hands should be washed after application; and partner exposure is a real question that only one program has studied systematically (the sildenafil-cream trial followed partners after 2,517 product-use events and found adverse-event parity with placebo, a product-specific result that does not transfer to compounded blends).

No blend has a label, so no blend has a contraindication list, and the honest substitute is ingredient-grade logic. The hard line: anyone using organic nitrates or nitrites in any form, or riociguat, should treat sildenafil-containing creams as contraindicated until absorption data exist, because the oral form's interaction is a strict contraindication and the cream's systemic delivery has never been measured. Pregnancy and breastfeeding sit behind zero data of any kind. Unstable cardiovascular disease makes an unquantified vasodilator stack a poor experiment. And a known allergy to any listed ingredient rules out the formulas containing it, which is one more reason to get the exact recipe in writing.

Ranked by evidence rather than alarm. Documented for this product class: local burning and application-site discomfort in every placebo-controlled trial of a genital arousal cream or oil that reported tolerability. Structural, by the product's nature: no FDA review of formula, strength, sterility or quality; formula changes between pharmacies that silently change the risk profile; and marketing that does not distinguish tested ingredients from untested ones. Unquantifiable, pending data: systemic vasodilator effects, because vulvar absorption of any ingredient from a compounded cream has never been published; the one adjacent measurement (undetectable serum theophylline in thigh-skin fat trials) does not transfer to mucosa. Unknown unknowns: long-term repeated vulvar exposure to methylxanthines, alpha-blockers and ergoloids has no safety literature at all.

For any blend as sold: none reported in any study, because there are no studies; pharmacy pages are marketing and report none either. From the closest trials, the class profile is local and short-lived: application-site discomfort was the most common treatment-related event with investigational sildenafil cream (occurring at similar rates with placebo cream), topical alprostadil produced mild transient genital burning typically under one minute, and the botanical Zestra caused genital burning in 14.6% of users versus none on placebo. Oral sildenafil's systemic profile (headache, flushing, visual effects, dyspepsia) is documented for tablets and would require meaningful absorption to appear from a cream; whether it does is unmeasured.

Interaction data for the blend: none exist. Ingredient-grade cautions that survive the uncertainty: nitrates, nitrite recreational drugs and riociguat (oral sildenafil contraindication; unmeasured cream absorption makes the risk unquantifiable rather than absent); blood-pressure medications (phentolamine is an alpha-blocker, sildenafil and methylxanthines are vasodilators; additive hypotension is the theoretical concern); and, for the theophylline-based recipes, the long oral theophylline interaction list is probably irrelevant at undetectable absorption but has never been checked for mucosal application. The only sourced interaction statement possible is the honest one: bring the exact formula and the full medication list to the same prescriber.

Zero data: no blend has any published study, so pregnancy, lactation and fertility effects are untested, and the neighboring cream trials enrolled non-pregnant women under monitoring. With absorption unmeasured, even exposure cannot be estimated. There is no sourced basis for calling any scream cream safe in pregnancy or while breastfeeding; the default is not to use it, and the exception belongs to a clinician who knows the case.

Compounded creams carry a pharmacy-assigned beyond-use date rather than an FDA-reviewed expiration, and stability testing of any scream cream recipe is unpublished, which follows from the larger fact that compounded formulas are not FDA-evaluated for quality. Storage instructions therefore come from the dispensing pharmacy and vary with the base and packaging (the documented products ship as 30-gram metered pumps). The honest storage guidance is procedural: follow the dispensed label, respect the beyond-use date, and treat color or texture change in an unreviewed product as a reason to stop.

The blend has no published pharmacokinetics: how much of any ingredient crosses vulvar and vaginal mucosa from a compounded cream has never been measured in a paper this site could find, and the developmental sildenafil-cream program has published efficacy and safety but no standalone PK study. What exists, printed at its true scope: oral sildenafil's approved-form numbers (bioavailability 41%, range 25 to 63%, peak about an hour fasted), which describe tablets, not skin; undetectable serum theophylline in the topical aminophylline fat-loss trials, which describes thigh skin, not mucosa; and partner-exposure accounting from the sildenafil-cream trial. The chips below carry these with their grades, absences included.

Whether any specific blend beats placebo (zero trials of any blend as sold, and none registered); whether one pharmacy's results transfer to another's (they cannot, by construction, since the drugs differ); how much of anything is absorbed (never measured, so the nitrate question cannot be closed in either direction); whether the sildenafil-cream subset finding survives a preregistered confirmatory trial (post hoc, industry-run, with a predecessor study never published and a registry record gone stale); and whether chronic vulvar exposure to this drug stack is safe long-term (no data). This block exists so the reader never mistakes graded neighboring evidence for evidence about the product itself.